TP53 mutations in synchronous and metachronous bilateral breast carcinomas

Suspitsin, Evgeny N.; Vu, Phuong; Hirvonen, Ari; Børresen-Dale, Anne Lise; Imyanitov, Evgeny N.

doi:10.1016/j.cancergencyto.2008.03.005

Cited by 6 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Perhaps, development of BC in these highly predisposed subjects involves somewhat distinct repertoire of molecular events. Unfortunately, only a few prior investigations reported a direct comparison of somatic events in bilateral vs. unilateral breast carcinomas [9,11,12]. Sequencing of TP53 gene detected similar frequency of mutations in biBC and [48], are designated by asterisks.…”

Section: Discussionmentioning

confidence: 98%

“…Sequencing of TP53 gene detected similar frequency of mutations in biBC and [48], are designated by asterisks. BRCA1 status assessment was done in all patients irrespectively of their age or family history; it included testing for three founder mutations (5382insC, 4153delA, and 185delAG), which constitute over 90% BRCA1 defects in Russia [49,50] uBC; however, tumors from synchronous biBC pairs tended to contain multiple nucleotide alterations within this gene, that was interpreted as potential indicator of genotoxic stress or failed genome defense [12]. A subset of contralateral neoplasms from metachronous biBC, but not other categories of breast tumors, were shown to have the so-called microsatellite instability phenotype (MSI-H); this observation was linked to the mutagenic effect of the adjuvant therapy applied for the treatment of the first malignancy [11].…”

Section: Discussionmentioning

confidence: 99%

“…biBC molecular characteristics have already been described with respect to genomic abnormalities, p53 mutations, oncogene amplifications, and expression of the subtype-specific markers [5,6,8,9,12]. The last decade brought into attention a novel class of molecules with a broad role in cancer development, i.e., microRNAs (miRs).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas

Iyevleva

Kuligina

Mitiushkina

et al. 2011

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

We analyzed the expression of several microRNAs (miRs) implicated in breast cancer (BC) pathogenesis (miR-21, miR-10b, miR17-5p, mir-31, miR-155, miR-200c, miR-18a, miR-205, and miR-27a) in 80 breast carcinomas obtained from patients with bilateral BC (biBC) and 40 cases of unilateral BC (uBC). Unexpectedly, three miRs (miR-21, miR-10b and miR-31) demonstrated significantly higher level of expression in biBC vs. uBC (P = 0.0001, 0.00004 and 0.0002, respectively). Increased contents of miR-21, miR-10b and miR-31 were observed in all categories of biBC tumors, i.e., in synchronous biBC as well as in first and second tumors from metachronous biBC cases. Synchronous biBC showed more similarity of miR expression profiles within pairs that the metachronous doublets (P = 0.004). This study suggests that bilateral breast tumors have somewhat distinct pattern of molecular events as compared to the unilateral disease.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas

Iyevleva

Kuligina

Mitiushkina

et al. 2011

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mutations in the BRCA1 and BRCA2 genes are the major factors that predispose women to familial breast cancer (2). Other genetic events such as mutations in the TP53 tumor suppressor gene and amplification of the ErbB2 oncogene are also important factors in breast cancer etiology (3,4). The TP53 mutations associated with Li-Fraumeni syndrome contribute to an early age of onset of several cancers, including breast cancer (5,6).…”

mentioning

confidence: 99%

An miR-502–Binding Site Single-Nucleotide Polymorphism in the 3′-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset

Song

Zheng

Liu

et al. 2009

Clinical Cancer Research

101

View full text Add to dashboard Cite

Purpose: MicroRNAs regulate gene expression by binding to the 3′-untranslated region (UTR) of target genes. Single-nucleotide polymorphisms of critical genes may affect their regulation by microRNAs. We have identified a single-nucleotide polymorphism within the miR-502 seed binding region in the 3′-UTR of the SET8 gene. SET8 methylates TP53 and regulates genome stability. We investigated the role of this SET8 singlenucleotide polymorphism and in concert with the TP53 codon 72 single-nucleotide polymorphism in the propensity for onset of breast cancer. Experimental Design: We measured the SET8 single-nucleotide polymorphisms in a case-control study on 1,110 breast cancer cases and 1,097 controls. Results: The SET8 CC and TP53 GG genotypes were independently associated with an earlier age of breast cancer onset in an allele-dose-dependent manner (for SET8, 52.2 years for TT, 51.4 for TC, and 49.5 for CC; and for TP53, 53.1 years for CC, 51.5 for GC, 50.7 for GG). Individuals with combined SET8 CC and TP53 GG genotypes developed cancer at a median age of 47.7 years as compared with 54.6 years for individuals with combined SET8 TT and TP53 CC genotypes. In the 51 breast cancer tissue samples tested, the SET8 CC genotype was associated with reduced SET8, but not miR-502, transcript levels. Conclusions: These data suggest that the miR-502-binding site single-nucleotide polymorphism in the 3′-UTR of SET8 modulates SET8 expression and contributes to the early development of breast cancer, either independently or together with the TP53 codon 72 single-nucleotide polymorphism. Larger studies with multiethnic groups are warranted to validate our findings. (Clin Cancer Res 2009;15(19):6292-300)

show abstract

“…Plusieurs auteurs ont étudié les caractéristiques épidémiologiques des patientes présentant un cancer synchrone bilatéral du sein. Le but de ces études était de définir une population à risque susceptible de bénéficier d'une surveillance ciblée, voire d'un traitement prophylactique [ 22 – 24 ]. Leurs résultats sont contradictoires [ 25 ].…”

Section: Discussionunclassified

Cancer du sein bilatéral synchrone au Maroc: caractéristiques épidémiologiques et cliniques

Boufettal¹,

Samouh²

2015

Pan Afr Med J

View full text Add to dashboard Cite

Préciser la fréquence, les facteurs de risque et le pronostic du cancer du sein bilatéral, à partir d'une étude rétrospective de 22 cas de cancer du sein bilatéral synchrone dans un pays du Maghreb. De 2002 à 2010, 625 patientes étaient prises en charge pour cancer du sein au service de Gynécologie-Obstétrique «C» du centre hospitalier universitaire de Casablanca. 22 cas de cancer bilatéral synchrone étaient diagnostiqués. Nos résultats sont comparés avec ceux de la littérature. La fréquence de la bilatéralité du cancer du sein synchrone était de 3,52% (22/625). L'intervalle de temps moyen entre les deux cancers est de 4 mois (0 à 6 mois). Les patientes âgées de moins de 40 ans lors du premier cancer avaient six fois plus de risque de développer un cancer au niveau du sein controlatéral que les femmes âgées de plus de 40 ans. Les patientes atteintes d'une tumeur T3 ou T4 avaient un risque neuf fois plus élevé que les autres. 90,9% (2/22) des cas des premiers cancers sont des adénocarcinomes infiltrants. Les types histologiques du premier et du douzième cancer étaient identiques dans 86,4% (19/22) des cas. Quant au pronostic, il dépend à la fois du stade du premier et du deuxième cancer et le traitement de ce dernier doit obéir aux mêmes règles du traitement du premier cancer. L'incidence du cancer bilatéral synchrone du sein est de 3,52% dans notre série. Le cancer du sein unilatéral constitue un facteur de risque de développement d'un cancer du sein controlatéral. Une surveillance à vie est nécessaire au cours d'un cancer du sein pour détecter un cancer controlatéral.

show abstract

TP53 mutations in synchronous and metachronous bilateral breast carcinomas

Cited by 6 publications

References 10 publications

High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas

High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas

An miR-502–Binding Site Single-Nucleotide Polymorphism in the 3′-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset

Cancer du sein bilatéral synchrone au Maroc: caractéristiques épidémiologiques et cliniques

Contact Info

Product

Resources

About